Acumen Pharmaceuticals, Inc.

ABOS · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$26,451-$40,950-$28,796-$37,154
Dep. & Amort.$0$47$45$44
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$2,498$2,474$0
Change in WC-$7,026$6,275-$7,362$8,221
Other Non-Cash$2,988$298-$482$1,674
Operating Cash Flow-$30,489-$31,832-$34,121-$27,215
Investing Activities
PP&E Inv.$0-$9-$79$0
Net Acquisitions$0$0$0$0
Inv. Purchases$0-$3,008-$35,048-$15,100
Inv. Sales/Matur.$40,511$41,500$63,816$44,763
Other Inv. Act.$0$0$0$0
Investing Cash Flow$40,511$38,483$28,689$29,663
Financing Activities
Debt Repay.$0$0$0-$739
Stock Issued$0$0$0$0
Stock Repurch.$0$0-$73-$9
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$37$739
Financing Cash Flow$0$0-$36-$9
Forex Effect$0$0$0$4
Net Chg. in Cash$10,022$6,651-$5,468$2,443
Supplemental Information
Beg. Cash$36,810$30,391$35,859$33,184
End Cash$46,832$37,042$30,391$35,627
Free Cash Flow-$30,489-$31,841-$34,200-$27,215